期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

弥漫大B细胞淋巴瘤预后生物标志物的进展 被引量：2

Research progress of prognostic biomarkers in diffuse large B-cell lymphoma
下载PDF
导出
摘要 弥漫大B细胞淋巴瘤是一种异质性肿瘤,捕获与患者预后相关的分子和蛋白标志物,建立生物标志物预后模型来预测患者的不良结局和进行风险分层,对更好地管理患者和指导治疗十分重要。 Diffuse large B-cell lymphoma（DLBCL） is a heterogenous group of neoplasm. The discovery of specific genetic alterations and the assessment of protein expression lead to the identification of molecular markers capable of predicting the outcome of DLBCL patients independently of clinical variables and finding better therapeutic target.
作者 孙璐 韦立新
机构地区 中国人民解放军总医院病理科
出处 《海南医学》 CAS 2014年第19期2879-2882,共4页 Hainan Medical Journal
关键词 弥漫大B细胞淋巴瘤 预后 生物标志物 Diffuse large B-cell lymphoma Prognosis Biomarker
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1Stein H, Warnke RA, Chart WC, et al. Diffuse large B-cell lympho- ma, not otherwise specified [M]//Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008: 233-237.
  • 2Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus ritux- imab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002, 346(4): 235-242.
  • 3Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of dif- fuse large B-cell lymphoma [J]. Blood, 2009, 113(24): 6069-6076.
  • 4Zelenetz A, Abramson J, Advani R, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin' s lymphomas [J]. J Natl Com- pr Canc Netw, 2010, 8(3): 288-334.
  • 5Diaz-Cano SJ. General morphological and biological features of neoplasms: integration of molecular findings [J]. Histopathology, 2008, 53(1): 1-19.
  • 6Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lyrnphoma [J]. J Clin Oncol, 2006, 24(6): 995-1007.
  • 7Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J]. Nature, 2000, 403(6769): 503-511.
  • 8Rosenwald A, Wright G, Chan WC, et al. The use of molecular pro- filing to predict survival aRer chemotherapy for diffuse large B-cell lymphoma [J]. N Engl J Med, 2002, 346(25): 1937-1947.
  • 9Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immu- nohistochemistry using a tissue microarray [J]. Blood, 2004, 103 (1): 275-282.
  • 10Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy [J]. Clin Cancer Res, 2009, 15(17): 5494-5502.

二级参考文献39

  • 1Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas:distributions of the major subtypes differ by geographic locations. Ann Oncol, 1998, 9: 717-720.
  • 2Peh SC. Host ethnicity influences non-Hodgkin's lymphoma (NHL) subtype frequency and Epstein-Barr virus association rate: the experience of a multiethnicpopulation in Malaysia. Histopathology, 2001, 38: 458-465.
  • 3Hans CP, Weiseuberger D, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2003, 103: 275-282.
  • 4Choi WW, Weisenburger DD, Greiner TC, et al. A New immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res, 2009, 15:5494-5502.
  • 5Petersen BL, Scrensen MC, Pedemen S, et al. Fluorescence in situ hybridization on formalin-fixed and paraffin-embedded tissue: optimizing the method. Appl Immunohistochem Mol Morphol, 2004, 12: 259-265.
  • 6Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathoi Lab Med, 2008, 132: 118-124.
  • 7Han's CP, Weisenburger DD, Greiner TC, et al.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistoehemistry using a tissue microarray. Blood, 2004, 103: 275-282.
  • 8Muris JJ, Meijer C J, Vos W, et al. Immunohistochemieal profiling based on bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 2006, 208: 714-723.
  • 9Chang CC, MeClintock S, Cleveland RP, et al.Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 2004, 28: 464-470.
  • 10Colomo L, Lopez-Guillermo A, Perales M, et al.Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101: 78-84.

共引文献25

同被引文献24

引证文献2

二级引证文献4

海南医学
2014年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部